Check-Cap (CHEK) Stock Price, News & Analysis

Company Overview

Check-Cap Ltd. (NASDAQ: CHEK) is a clinical-stage medical device company focused on the development of non-invasive screening technologies for colorectal cancer. The company’s lead product, the C-Scan® system, is designed to provide a full-colonic 360° visualization by combining an ingestible X-ray emitting capsule with an external detector array and proprietary image reconstruction algorithms. Intended as a minimally invasive alternative to traditional colonoscopy, the C-Scan system aims to improve patient comfort and compliance while maintaining high sensitivity for detecting polyps and early-stage lesions.

The C-Scan procedure involves the patient ingesting the capsule, which passes naturally through the gastrointestinal tract. During its transit, the capsule emits low-dose X-rays that are captured by detectors worn externally around the abdomen. Data collected by the system are then processed by software to generate high-resolution, panoramic images of the colon lining. This approach seeks to address limitations of stool-based tests and virtual colonoscopy, offering clinicians detailed anatomical views without sedation or insufflation.

Founded in Israel, Check-Cap maintains its headquarters in Caesarea along with operations in the United States, where it conducts clinical trials and regulatory activities. The company has completed multiple early-stage studies and has been advancing toward pivotal trials required for regulatory clearances in both European and U.S. markets. Check-Cap’s development strategy includes collaborations with leading gastroenterology centers to validate clinical efficacy and support future commercial rollout.

Check-Cap is led by a management team with extensive experience in medical imaging, device development and gastroenterology. The company continues to advance its C-Scan platform through ongoing research, regulatory engagement and strategic partnerships, aiming to transform colorectal cancer screening by offering a patient-friendly solution with broad applicability in routine preventive care.

Key Stats

• Today's Range: $1.50 to $1.67
• 50-Day Range: $1.21 to $1.98
• 52-Week Range: $0.59 to $3.13
• Volume: 58,962 shs
• Average Volume: 1.29 million shs
• Market Capitalization: $9.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Company Calendar

• Last Earnings: 11/27/2023
• Today: 6/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CHEK
• CIK: 1610590
• Web: www.check-cap.com
• Phone: 972546706451
• Fax: 972-4821-1267
• Employees: 80
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.25) per share
• Price / Book: -6.46

Miscellaneous

• Outstanding Shares: 5,851,000
• Free Float: 5,823,000
• Market Cap: $9.45 million
• Optionable: Not Optionable
• Beta: 0.41